Biogen Inc. (BIIB) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
BIIB Revenue Growth
Revenue Breakdown (FY 2025)
BIIB's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
By Geography
BIIB Revenue Analysis (2014–2025)
As of May 7, 2026, Biogen Inc. (BIIB) generated trailing twelve-month (TTM) revenue of $9.86 billion, reflecting modest growth of +1.9% year-over-year. The most recent quarter (Q1 2026) recorded $2.48 billion in revenue, up 8.7% sequentially.
Looking at the longer-term picture, BIIB's 5-year compound annual growth rate (CAGR) stands at -6.1%, indicating revenue contraction over this period. The company achieved its highest annual revenue of $14.38 billion in 2019.
Revenue diversification analysis shows BIIB's business is primarily driven by MS Product Revenues (42%), TYSABRI product (17%), and SPINRAZA (16%).
When compared to Healthcare sector peers including REGN (+5.9% YoY), VRTX (+10.4% YoY), and BMRN (+9.9% YoY), BIIB has underperformed the peer group in terms of revenue growth. Compare BIIB vs REGN →
BIIB Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| BIIBCurrent | $9.9B | +1.9% | -6.1% | 19.1% | |
 REGN | $14.3B | +5.9% | +11.0% | 24.9% | |
 VRTX | $12.1B | +10.4% | +14.2% | 39.4% | |
 BMRN | $3.2B | +9.9% | +11.6% | 16.6% | |
 ALNY | $3.7B | +82.6% | +49.8% | 13.5% | |
 GILD | $28.8B | +2.4% | +5.1% | 5.8% |
BIIB Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $9.81B | +1.4% | $6.91B | 70.5% | $1.88B | 19.1% |
| 2024 | $9.68B | -1.6% | $7.37B | 76.1% | $2.49B | 25.7% |
| 2023 | $9.84B | -3.3% | $7.30B | 74.2% | $2.10B | 21.3% |
| 2022 | $10.17B | -7.4% | $7.90B | 77.6% | $2.89B | 28.4% |
| 2021 | $10.98B | -18.3% | $8.87B | 80.8% | $2.79B | 25.4% |
| 2020 | $13.44B | -6.5% | $11.64B | 86.6% | $4.59B | 34.2% |
| 2019 | $14.38B | +6.9% | $12.42B | 86.4% | $7.04B | 49.0% |
| 2018 | $13.45B | +9.6% | $11.64B | 86.5% | $5.89B | 43.8% |
| 2017 | $12.27B | +7.2% | $10.64B | 86.7% | $5.35B | 43.6% |
| 2016 | $11.45B | +6.4% | $10.02B | 87.5% | $5.15B | 45.0% |
Full BIIB Stock Analysis
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
See BIIB's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs BIIB Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare BIIB vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonBIIB — Frequently Asked Questions
Quick answers to the most common questions about buying BIIB stock.
Is BIIB's revenue growth accelerating or slowing?
BIIB revenue growth slowed to +1.9%, below the 5-year CAGR of -6.1%. TTM revenue is $9.9B. The deceleration marks a shift from historical growth rates.
What is BIIB's long-term revenue growth rate?
Biogen Inc.'s 5-year revenue CAGR of -6.1% reflects the variable expansion pattern. Current YoY growth of +1.9% is near this long-term average.
How is BIIB's revenue distributed by segment?
BIIB reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.